Article Text

Download PDFPDF
Guideline review
Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment
  1. Danujan Sriranganathan1,
  2. Jonathan P Segal1,
  3. Mayur Garg2,3
  1. 1Department of Gastroenterology, Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UK
  2. 2Department of Gastroenterology, Northern Health, Epping, Victoria, Australia
  3. 3Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
  1. Correspondence to Danujan Sriranganathan, Gastroenterology, Hillingdon Hospitals NHS Foundation Trust, Uxbridge UB8 3NN, UK; danujan.sriranganathan{at}nhs.net

Abstract

In 2019, the European Crohn’s and Colitis Organisation released guidelines for the medical management of Crohn’s disease, concerning the induction of remission, the maintenance of remission and the treatment of fistulising perianal disease. This review summarises the key recommendations regarding the use of biologics in these settings.

  • Crohn's disease

Statistics from Altmetric.com

Footnotes

  • Contributors DS, JPS and MG came up with the concept, drafted the manuscript and contributed equally. All authors agreed to the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MG has served on the advisory board of Pfizer and Pharmacosmos and has received speaker fees, research or travel grants from Abbvie, Celltrion, Janssen, Pfizer, Pharmacosmos, Takeda and Vifor. JPS has received speaker fees for Janssen, Abbvie and Takeda.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.